Literature DB >> 3079597

Intravenous administration of pulsatile gonadotropin-releasing hormone in hypothalamic amenorrhea: effects of dosage.

N Santoro, M E Wierman, M Filicori, J Waldstreicher, W F Crowley.   

Abstract

Eighteen women with well characterized hypothalamic amenorrhea underwent 30 cycles of pulsatile GnRH treatment in an effort to examine the role of GnRH dosage in pituitary and ovarian responses. GnRH was administered iv at 2 doses (25 and 100 ng/kg bolus) at a physiological range of frequencies (90 and 60 min) in the follicular phase of the induced cycles. After demonstration of ovulation by ultrasound and clinical parameters, the frequency of GnRH administration was progressively slowed from every 60 min to every 90 min and then to every 240 min to mimic the slowing of endogenous LH secretion that occurs during the luteal phase in normal women. The results of these induced cycles were compared to those of 62 ovulatory cycles from normal women. Overall clinical and biochemical results revealed the following. Patients receiving doses of 25 ng/kg GnRH successfully ovulated only 80% of the time, with recruitment of a single dominant follicle. Two of 5 patients became pregnant. Peak estradiol levels were significantly lower than normal [261 +/- 33 (+/- SE) vs. 342 +/- 11 pg/ml, respectively; P less than 0.02]. Integrated luteal phase progesterone production was also significantly reduced in the 25 ng/kg group compared to normal (78 +/- 17 vs. 145 +/- 8 ng/ml/entire luteal phase, respectively; P less than 0.02). All women receiving bolus doses of 100 ng/kg GnRH ovulated; maturation of multiple follicles occurred in 5 of 20 cycles, and 6 of 7 women conceived. Peak estradiol values were significantly higher than those in either normal women or the 25 ng/kg group (478 +/- 48 pg/ml; P less than 0.02 for both), with integrated luteal phase progesterone levels significantly higher than those in patients receiving the 25 ng/kg dose (196 +/- 25 ng/ml/luteal phase; P less than 0.02). This study demonstrates that ovulation and fertility can be achieved with a physiological frequency regimen of pulsatile GnRH administration using bolus doses of both 25 and 100 ng/kg in women with hypothalamic amenorrhea; the 25 ng/kg dose of GnRH may represent a threshold of stimulation of the pituitary-ovarian axis and recreates cycles with an inadequate luteal phase; and a 100 ng/kg dose of GnRH may well cause a supraphysiological stimulation of the pituitary-gonadal axis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3079597     DOI: 10.1210/jcem-62-1-109

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Functional Hypogonadotropic Hypogonadism in Men: Underlying Neuroendocrine Mechanisms and Natural History.

Authors:  Andrew A Dwyer; Niraj R Chavan; Hilana Lewkowitz-Shpuntoff; Lacey Plummer; Frances J Hayes; Stephanie B Seminara; William F Crowley; Nelly Pitteloud; Ravikumar Balasubramanian
Journal:  J Clin Endocrinol Metab       Date:  2019-08-01       Impact factor: 5.958

2.  Pulsatile secretion of parathyroid hormone and its action on a type I and type II PTH receptor: a hypothesis for understanding osteoporosis.

Authors:  R D Hesch; G Brabant; E F Rittinghaus; M J Atkinson; H Harms
Journal:  Calcif Tissue Int       Date:  1988-06       Impact factor: 4.333

3.  Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b.

Authors:  Konstantina Kyritsi; Fanyin Meng; Tianhao Zhou; Nan Wu; Julie Venter; Heather Francis; Lindsey Kennedy; Paolo Onori; Antonio Franchitto; Francesca Bernuzzi; Pietro Invernizzi; Kelly McDaniel; Romina Mancinelli; Domenico Alvaro; Eugenio Gaudio; Gianfranco Alpini; Shannon Glaser
Journal:  Am J Pathol       Date:  2017-05-12       Impact factor: 4.307

4.  The impact of dosage on ovulation induction by pulsatile gonadotropin-releasing hormone (Gn-RH) in hypothalamic amenorrhea.

Authors:  A Caruso; A Lanzone; A M Fulghesu; S Mancuso
Journal:  J Endocrinol Invest       Date:  1987-10       Impact factor: 4.256

5.  Kisspeptin administration to women: a window into endogenous kisspeptin secretion and GnRH responsiveness across the menstrual cycle.

Authors:  Yee-Ming Chan; James P Butler; Valerie F Sidhoum; Nancy E Pinnell; Stephanie B Seminara
Journal:  J Clin Endocrinol Metab       Date:  2012-05-10       Impact factor: 5.958

6.  Atrazine and breast cancer: a framework assessment of the toxicological and epidemiological evidence.

Authors:  James W Simpkins; James A Swenberg; Noel Weiss; David Brusick; J Charles Eldridge; James T Stevens; Robert J Handa; Russell C Hovey; Tony M Plant; Timothy P Pastoor; Charles B Breckenridge
Journal:  Toxicol Sci       Date:  2011-07-18       Impact factor: 4.849

7.  Subcutaneous infusion of kisspeptin-54 stimulates gonadotrophin release in women and the response correlates with basal oestradiol levels.

Authors:  Shakunthala Narayanaswamy; Channa N Jayasena; Noel Ng; Risheka Ratnasabapathy; Julia K Prague; Deborah Papadopoulou; Ali Abbara; Alexander N Comninos; Paul Bassett; Stephen R Bloom; Johannes D Veldhuis; Waljit S Dhillo
Journal:  Clin Endocrinol (Oxf)       Date:  2015-12-17       Impact factor: 3.478

Review 8.  Current understanding of hypothalamic amenorrhoea.

Authors:  Rachel E Roberts; Linda Farahani; Lisa Webber; Channa Jayasena
Journal:  Ther Adv Endocrinol Metab       Date:  2020-07-30       Impact factor: 3.565

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.